Safety and efficacy of first-generation and second-generation drug-eluting stents in the setting of acute coronary syndromes

Journal of Cardiovascular Medicine

Volumn 15, Issue 7, 2014, Pages 532-542

  Gorla, Riccardo ^a   Loffi, Marco ^b   Verna, Edoardo ^a   Margonato, Alberto ^b   Salerno Uriarte, Jorge ^a  

^a OSPEDALE DI CIRCOLO   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

acute coronary syndromes; bare metal stent; drug eluting stent; non ST elevation acute coronary syndrome; ST elevation myocardial infarction

Indexed keywords

ANTITHROMBOCYTIC AGENT; EVEROLIMUS; PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; BARE METAL STENT; COCHRANE LIBRARY; DRUG ELUTING STENT; FIRST GENERATION DRUG ELUTING STENT; HUMAN; MEDICAL LITERATURE; MEDLINE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; REGISTER; REVIEW; SECOND GENERATION DRUG ELUTING STENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SYSTEMATIC REVIEW; CORONARY RESTENOSIS; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATIONS; PROCEDURES; PROSTHESIS; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATIONS; PROSTHESIS DESIGN; TREATMENT OUTCOME;

EID: 84902519952     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e328365c0fc     Document Type: Review

References (68)

1. Gruntzig AR, Senning A, Siegenthaler WE. Non operative dilatation of coronary-Artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301:61-68.
2. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987; 316:701-706.
3. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drugeluting and bare-metal stents: a collaborative network meta-Analysis. Lancet 2007; 370:937-948.
4. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001; 104:852-855.
5. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stents versus abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005; 293:2109-2117.
6. Valgimigli M, Campo G, Arcozzi C, et al. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa inhibitor infusion in patients with myocardial infarction. J Am Coll Cardiol 2007; 50:138-145.
7. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355:1093-1104.
8. Spaulding C, Teiger E, Commeau P, et al. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). JACC Cardiovasc Interv 2011; 4:14-23.
9. Valgimigli M, Campo G, Gambetti S, et al. Three-year follow-up of the MULTicentre evaluation of Single high-dose Bolus TiRofiban versus Abcximab with Sirolimus-eluting stent or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY). Int J Cardiol 2013; 165:134-141.
10. Atary JZ, Van der Hoeven BL, Liem SS, et al. Three-year outcome of sirolimus-eluting versus bare-metal stents for the treatment of ST-segment elevation myocardial infarction (from the MISSION! Intervention Study). Am J Cardiol 2010; 106:4-12.
11. Menichelli M, Parma A, Pucci E, et al. Randomized trial of sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction. J Am Coll Cardiol 2007; 19:1924-1930.
12. Violini R, Musto C, De Felice F, et al. Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial. J Am Coll Cardiol 2010; 55:810-814.
13. Grube E, Silber S, Hauptmann KE, Mueller R, et al. TAXUS I: six-And twelve-month results from a randomized, double-blind trial on a slowrelease paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107:38-42.
14. Turco MA, Ormiston JA, Popma JJ, et al. Polymer-based, paclitaxel-eluting TAXUS Libertè stent in de novo lesions: the pivotal TAXUS ATLAS trial. J Am Coll Cardiol 2007; 49:1676-1683.
15. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006; 355:1105-1113.
16. Vink MA, Dirksen MT, Suttorp MJ, et al. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. JACC Cardiovasc Interv 2011; 4:24-29.
17. Tierala I. Helsinki Area Acute Myocardial Infarction Treatment Re-Evaluation-Should the Patients Get a Drug-Eluting or Normal Stent (HAAMU-STENT). Presented at the Transcatheter Cardiovascular Therapeutics meeting (TCT 2006). Washington, DC.
18. Chechi T, Vittori G, Biondi Zoccai GG, et al. Single-centre randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION). J Interv Cardiol 2007; 20:282-291.
19. Stone GW. HORIZONS AMI: a prospective randomized comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors during primary angioplasty in acute myocardial infarction: 12 month results. Paper presented at Transcatheter therapeutics meeting; 15 October 2008.
20. Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxeleluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011; 377:2193-2204.
21. Kaltoft A, Kelbaek H, Thuesen L, et al. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) trial. J Am Coll Cardiol 2010; 56:641-645.
22. Di Lorenzo E, De Luca G, Sauro R, et al. The PASEO (Paclitaxel or Sirolimus-eluting stent versus Bare-metal stent in primary angioplasty) randomized trial. JACC Cardiovasc Interv 2009; 2:515-523.
23. Di Lorenzo E, Sauro R, Varricchio A, et al. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the Paclitaxel or Sirolimus-eluting stent versus Bare-metal stent in primary angioplasty (PASEO) randomized trial. Am Heart J 2009; 158:e43-e50.
24. Kim HS, Lee JH, Lee SW, et al. Long-term safety and efficacy of sirolimusvs. paclitaxel-eluting stent implantation for acute ST-elevation myocardial infarction: 3-year follow-up of the PROSIT trial. Int J Cardiol 2011; 147:253-257.
25. Lemos PA, Saia F, Hofma SH, et al. Short-term and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 2004; 43:704-708.
26. Daemen J, Tanimoto S, Garcia-Garcia HM, et al. Comparison of three-year clinical outcome of sirolimus and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH registries). Am J Cardiol 2007; 99:1027-1032.
27. Steg PG, Fox KAA, Eagle KA, et al. Mortality following placement of drugeluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2009; 30:321-329.
28. Hannan E, Racz M, Walford G, et al. Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2008; 1:129-135.
29. Brodie BR, Stuckey T, Downey W, et al. Outcomes with drug-eluting stents versus bare metal stents in acute ST-elevation myocardial infarction: results from the Strategic Transcatheter Evaluation of New Therapies (STENT) Group. Catheter Cardiovasc Interven 2008; 72:893-900.
30. Pedersen S, Galatius S, Mogelvang R, et al. Long-term clinical outcome in STEMI patients treated with primary PCI and drug-eluting or bare-metal stents: insights from a high-volume single-centre registry. J Invasive Cardiol 2011; 23:328-333.
31. Sattur S, Orshaw P, Boura J, Harjai KJ. Long-term safety and effectiveness of drug-eluting stents compared to bare metal stents in ST elevation myocardial infarction: findings from the Guthrie Health Off-label Stent (GHOST) Registry. J Interv Cardiol 2012; 25:118-125.
32. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48:193-202.
33. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008; 52:333-342.
34. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004; 109:701-705.
35. Kereiakes DJ, Cox DA, Hermiller JB, et al. Usefulness of a cobalt-chromium coronary stent alloy. Am J Cardiol 2003; 92:463-466.
36. Park DW, Kim YH, Yun SC, et al. Comparison of zotarolimus-eluting stents with sirolimus-And paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stents with sirolimus-And paclitaxel-eluting stents for coronary lesions) randomized trial. J Am Coll Cardiol 2010; 56:1187-1195.
37. Rasmussen K, Maeng M, Kaltoft A, et al. Efficacy and safety of zotarolimuseluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet 2010; 375:1090-1099.
38. Leon MB, Mauri L, Popma JJ, et al. Randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 2010; 55:543-554.
39. Shelton RJ, Chitkara K, Singh R, et al. Three-year clinical outcome with the Endeavor zotarolimus-eluting stent in primary percutaneous coronary intervention for ST elevation myocardial infarction: the Endeavor primary PCI study (E-PPCI). J Interv Cardiol 2011; 24:542-548.
40. Lee CW, Park DW, Lee SH, et al. Comparison of the efficacy and safety of zotarolimus-, sirolimus-And paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. Am J Cardiol 2009; 104:1370-1376.
41. Kim HK, Jeong MH, Ahn YK, et al. Comparison of outcomes between zotarolimus-And sirolimus-eluting stents in patients with ST-segment elevation acute myocardial infarction. Am J Cardiol 2010; 105:813-818.
42. Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity early in high risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011; 123:1400-1409.
43. Garg S, Serruys PW, Onuma Y, et al. Three-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions. The SPIRIT II trial. J Am Coll Cardiol Interv 2009; 2:1190-1198.
44. Stone GW. The XIENCE V-PROMUS everolimus-eluting stent: comprehensive update of the clinical trial program. Paper presented at Transcatheter Cardiovascular Therapeutics; 21 September 2009 San Francisco, CA.
45. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxeleluting stents in coronary artery disease. N Engl J Med 2010; 362:1663-1674.
46. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimuseluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010; 375:201-209.
47. Bangalore S, Kumar S, Fusaro M, et al. Outcomes with various drug-eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patients years of follow-up from randomised trials. BMJ 2012; 345:e5170.
48. Sabate M, Cequier A, Iniguez A, et al. Everolimus-eluting stent versus baremetal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012; 380:1482-1490.
49. Sudhir K, Hermiller JB, Naidu SS, et al. Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V everolimuseluting stents: one-year results from the XIENCE V USA study. Cath Cardiovasc Interv 2013; 82:E385-E394.
50. Hofma SH, Brouwer J, Velders MA, et al. Second-generation everolimuseluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial. J Am Coll Cardiol 2012; 60:381-387.
51. Kehdi E, Gomes M, Joesoef KS, et al. Everolimus-eluting stents and paclitaxel-eluting stents in patients presenting with myocardial infarction: insights from the two year results of the COMPARE prospective randomised controlled trial. EuroIntervention 2012; 7:1376-1385.
52. Chen KY, Rha SW, Wang L, et al. Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction. JACC Cardiovasc Interv 2012; 5:936-945.
53. Moses JW, Mehran R, Nikolsky E, et al. Outcomes with the paclitaxeleluting stent in patients with acute coronary syndromes. Analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005; 45:1165-1171.
54. Mauri L, Silbaugh T, Garg P, et al. Drug-eluting or bare metal stents for acute myocardial infarctions. N Engl J Med 2008; 359:1330-1342.
55. Kukreja N, Onuma Y, Garcia-Garcia HM, et al. The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents. JACC Cardiovasc Interv 2009; 2:534-541.
56. Li Y, Torguson R, Syed AI, et al. Effect of drug eluting stents on frequency of repeat revascularization in patients with unstable angina pectoris or non-ST-elevation myocardial infarction. Am J Cardiol 2009; 104:1654-1659.
57. Hannan EL, Samadashvili Z, Walford G, et al. Comparison of outcomes for patients receiving drug-eluting versus bare metal stents for non-STsegment elevation myocardial infarction. Am J Cardiol 2011; 107:1311-1318.
58. Harjai KJ, Sattur S, Orshaw P, et al. Long-term safety and effectiveness of drug-eluting stents compared to bare metal stents following successful PCI in non-ST-elevation myocardial infarction: findings from the Guthrie Health Off-label StenT (GHOST) Registry. J Interv Cardiol 2012; 25:28-36.
59. Thim T, Maeng M, Kaltoft A, et al. Zotarolimus-eluting vs. sirolimus-eluting coronary stents in patients with and without acute coronary syndromes: a SORT OUT III substudy. Eur J Clin Invest 2012; 42:1047-1054.
60. Kalesan B, Stefanini GG, Räber L, et al. Long-term comparison of everolimus-And sirolimus-eluting stents in patients with acute coronary syndromes. J Am Coll Cardiol Cardiovasc Interv 2012; 5:145-154.
61. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-Analysis. Lancet 2012; 379:1393-1402.
62. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Clinical outcomes with drug-eluting and bare metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network metaanalysis. J Am Coll Cardiol 2013; 62:496-504.
63. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-2015.
64. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045-1057.
65. Biondi-Zoccai G, Lotrionte M, Agostoni P, et al. Adjusted indirect comparison meta-Analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol 2011; 150:325-331.
66. Heft G. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation. Arch Cardiovasc Dis 2013; 106:271-273.
67. Lim MY, Pruthi RK. Outcomes of management of acute coronary syndrome in patients with congenital bleeding disorders: a single center experience and review of the literature. Thromb Res 2012; 130:316-322.
68. Greenhalgh J, Hockenhull J, Rao N, Dundar Y, Dickson RC, Bagust A. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database Syst Rev 2010;CD004587. 10.1002/14651858.CD004587. pub2.